Compare · CRDF vs LSTA
CRDF vs LSTA
Side-by-side comparison of Cardiff Oncology Inc. (CRDF) and Lisata Therapeutics Inc. (LSTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. CRDF focuses on Biotechnology: Biological Products (No Diagnostic Substances), while LSTA focuses on Biotechnology: Pharmaceutical Preparations.
- CRDF is the larger of the two at $56.6M, about 4.3x LSTA ($13.1M).
- LSTA has been more active in the news (8 items in the past 4 weeks vs 7 for CRDF).
- CRDF has more recent analyst coverage (15 ratings vs 0 for LSTA).
- Company
- Cardiff Oncology Inc.
- Lisata Therapeutics Inc.
- Price
- -
- -
- Market cap
- $56.6M
- $13.1M
- 1M return
- -25.08%
- -
- 1Y return
- -64.67%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 7
- 8
- Recent ratings
- 15
- 0
Cardiff Oncology Inc.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Latest CRDF
- Cardiff Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Cardiff Oncology Inc.
- Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update
- Cardiff Oncology to Participate in the UBS Global Biopharma Conference
- SEC Form 3 filed by Cardiff Oncology Inc.
- SEC Form 8-K filed by Cardiff Oncology Inc.
- Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer
- SEC Form 8-K filed by Cardiff Oncology Inc.
- Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
- Cardiff Oncology upgraded by H.C. Wainwright with a new price target
Latest LSTA
- SEC Form 10-Q filed by Lisata Therapeutics Inc.
- SEC Form S-3 filed by Lisata Therapeutics Inc.
- SEC Form S-8 filed by Lisata Therapeutics Inc.
- Amendment: Lisata Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form DEFA14A filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of Medicine
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences
- SEC Form DEF 14A filed by Lisata Therapeutics Inc.
- SEC Form 3 filed by Lisata Therapeutics Inc.